Fucosylation Inhibitor Development Service

Fucosylation Inhibitor Development Service

Fucosylation Inhibitor Development Service at CD BioGlyco

At CD BioGlyco, we are dedicated to the development of various types of Glycosylation Inhibitors. For example, Metabolic Interconversion Inhibitor Development Service, N-Glycosylation Inhibitor Development Service, O-Glycosylation Inhibitor Development Service, Capping Modification Inhibitor Development Service, and so on. As for capping modification inhibitor development, we provide inhibitor development solutions for each of the fucosyltransferases through functional characterization of the enzyme.

Our inhibitor development focuses on the following processes:

  • Screening and synthesis
    Firstly, we identify potential inhibitors by high-throughput screening in protein databases. Small molecules targeting key interaction networks are screened by molecular docking specificity. Molecular dynamics is used to simulate the dynamic changes during small molecule-protein interactions. Then, we use the screened compounds as templates to synthesize their analogs.
  • Structural characterization
    We utilize the sodium dodecyl sulfate-polyacrylamide gel electrophoresis to determine the structure as well as the molecular weight of the synthesized inhibitors. The X-single crystal diffraction technique is employed to determine their crystal structures and the binding sites on the surface of the molecule. Lastly, we provide the determination of the inhibition rate.

The specific services we provide include but are not limited to:

Fig.1 Types of fucosyltransferase inhibitors. (CD BioGlyco)Fig.1 Types of fucosyltransferase inhibitors. (CD BioGlyco)


  • Most of the tumor cell production, metastasis, and spread are associated with fucosylation on the cell surface. Our fucosylation inhibitor development service can be used in anti-tumor research.
  • The development of fucosylation inhibitors can be used to study cell-cell and protein-glycan interactions.
  • The development of fucoidan glycosylation inhibitors can be used to explore the process by which glycosylation occurs on the cell surface.


  • We offer a variety of fucosyltransferase inhibitor development services and provide custom development solutions for our clients.
  • We have a wide range of ideas for the development of fucoidan glycosylation inhibitors to ensure client satisfaction.
  • Our inhibitor research and development technology is at the forefront of the world and is being developed over the long term.

CD BioGlyco has extensive experience in the development of glycosylation inhibitors, providing many types of glycosylation inhibitor development. Every step of our process has gone through multiple quality checks to ensure that we provide our clients with satisfactory development programs and results. Please feel free to contact us if you are interested in our services and have any questions.


  1. Lv, Y.X.; et al. Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors. Drug Discovery Today. 2023, 28(1): 103394.
  2. García-García, A.; et al. FUT8-directed core fucosylation of N-glycans is regulated by the glycan structure and protein environment. ACS Catalysis. 2021, 11(15): 9052-9065.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.